Karyopharm (KPTI) Q2 FY26 earnings call

Karyopharm is sharpening its focus on hematology, advancing selinexor's sNDA for myelofibrosis and growing its multiple myeloma business, XPOVIO. The company is actively addressing a near-term liquidity challenge and debt covenant issue while leveraging its established commercial platform for a potential myelofibrosis launch in early 2027. This strategic pivot follows the disappointing results of the XPORT-EC-042 study in endometrial cancer.